Chemed (CHE)
Market Price (12/4/2025): $430.72 | Market Cap: $6.2 BilSector: Health Care | Industry: Health Care Services
Chemed (CHE)
Market Price (12/4/2025): $430.72Market Cap: $6.2 BilSector: Health CareIndustry: Health Care Services
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% | Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -88% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% | ||
| Attractive yieldFCF Yield is 5.6% | ||
| Low stock price volatilityVol 12M is 29% | ||
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Water Infrastructure. Themes include Geriatric Care, and Wastewater Management. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% |
| Attractive yieldFCF Yield is 5.6% |
| Low stock price volatilityVol 12M is 29% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Water Infrastructure. Themes include Geriatric Care, and Wastewater Management. |
| Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -88% |
Valuation, Metrics & Events
CHE Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are five key points explaining Chemed's stock movement by -5.8% during the approximate time period from August 31, 2025, to December 4, 2025:
1. Chemed's Second Quarter 2025 Earnings Miss.
Although reported just before the specified period on July 29, 2025, Chemed's second-quarter earnings significantly missed analyst expectations for both earnings per share (EPS) and revenue, leading to an 8.8% stock price drop in after-hours trading. The company also revised its full-year 2025 EPS guidance downward from previous estimates, setting a cautious tone that likely influenced sentiment in the early part of the August-December timeframe.
2. Third Quarter 2025 Adjusted EPS and EBITDA Miss.
For the third quarter of 2025, reported on October 28, Chemed's adjusted diluted EPS of $5.27 fell below analysts' consensus estimates. Additionally, the adjusted EBITDA of $109 million missed analyst expectations of $113.9 million, indicating a decline in operational profitability.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CHE Return | 22% | -0% | -3% | 15% | -9% | -19% | -0% |
| Peers Return | 1% | 48% | -7% | 28% | 7% | 43% | 172% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| CHE Win Rate | 58% | 58% | 42% | 67% | 58% | 40% | |
| Peers Win Rate | 43% | 62% | 48% | 55% | 52% | 70% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| CHE Max Drawdown | -20% | -23% | -18% | -4% | -11% | -22% | |
| Peers Max Drawdown | -40% | -4% | -25% | -14% | -15% | -10% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: THC, WTS, NHC, CVS, CI. See CHE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | CHE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -26.7% | -25.4% |
| % Gain to Breakeven | 36.4% | 34.1% |
| Time to Breakeven | 547 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.7% | -33.9% |
| % Gain to Breakeven | 44.3% | 51.3% |
| Time to Breakeven | 139 days | 148 days |
| 2018 Correction | ||
| % Loss | -20.2% | -19.8% |
| % Gain to Breakeven | 25.4% | 24.7% |
| Time to Breakeven | 127 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -54.6% | -56.8% |
| % Gain to Breakeven | 120.1% | 131.3% |
| Time to Breakeven | 930 days | 1480 days |
Compare to THC, WTS, NHC, CVS, CI
In The Past
Chemed's stock fell -26.7% during the 2022 Inflation Shock from a high on 1/25/2021. A -26.7% loss requires a 36.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to CHE. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| 02292020 | CHE | Chemed | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 22.5% | 6.9% | -15.8% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| 02292020 | CHE | Chemed | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 22.5% | 6.9% | -15.8% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Chemed
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 240.07 |
| Mkt Cap | 13.9 |
| Rev LTM | 11,688 |
| Op Inc LTM | 447 |
| FCF LTM | 931 |
| FCF 3Y Avg | 998 |
| CFO LTM | 1,449 |
| CFO 3Y Avg | 1,459 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.6% |
| Rev Chg 3Y Avg | 7.1% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Mgn LTM | 13.9% |
| Op Mgn 3Y Avg | 13.8% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 12.0% |
| CFO/Rev 3Y Avg | 11.3% |
| FCF/Rev LTM | 8.5% |
| FCF/Rev 3Y Avg | 8.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 13.9 |
| P/S | 1.1 |
| P/EBIT | 14.5 |
| P/E | 20.8 |
| P/CFO | 12.5 |
| Total Yield | 6.0% |
| Dividend Yield | 1.4% |
| FCF Yield 3Y Avg | 6.9% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.6% |
| 3M Rtn | 1.5% |
| 6M Rtn | 17.8% |
| 12M Rtn | 21.0% |
| 3Y Rtn | 31.3% |
| 1M Excs Rtn | 2.7% |
| 3M Excs Rtn | -4.8% |
| 6M Excs Rtn | 3.0% |
| 12M Excs Rtn | 7.0% |
| 3Y Excs Rtn | -35.7% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| VITAS | 1,315 | 1,202 | 1,261 | 1,335 | 1,281 |
| Roto-Rooter | 949 | 933 | 878 | 745 | 657 |
| Corporate | 0 | 0 | |||
| Total | 2,264 | 2,135 | 2,139 | 2,080 | 1,939 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Roto-Rooter | 227 | 211 | 151 | ||
| VITAS | 184 | 196 | 295 | ||
| Corporate | -70 | -64 | -57 | ||
| Total | 341 | 343 | 390 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Roto-Rooter | 188 | 186 | 166 | 120 | 104 |
| VITAS | 159 | 131 | 162 | 239 | 156 |
| Corporate | -74 | -68 | -60 | -40 | -40 |
| Total | 273 | 250 | 269 | 319 | 220 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| VITAS | 779 | 750 | 693 | 672 | 663 |
| Roto-Rooter | 523 | 512 | 513 | 499 | 507 |
| Corporate | 366 | 179 | 136 | 264 | 97 |
| Total | 1,668 | 1,442 | 1,343 | 1,435 | 1,268 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10312025 | 10-Q 9/30/2025 |
| 6302025 | 7312025 | 10-Q 6/30/2025 |
| 3312025 | 4282025 | 10-Q 3/31/2025 |
| 12312024 | 2282025 | 10-K 12/31/2024 |
| 9302024 | 11012024 | 10-Q 9/30/2024 |
| 6302024 | 7262024 | 10-Q 6/30/2024 |
| 3312024 | 4292024 | 10-Q 3/31/2024 |
| 12312023 | 2292024 | 10-K 12/31/2023 |
| 9302023 | 10272023 | 10-Q 9/30/2023 |
| 6302023 | 7282023 | 10-Q 6/30/2023 |
| 3312023 | 4282023 | 10-Q 3/31/2023 |
| 12312022 | 2272023 | 10-K 12/31/2022 |
| 9302022 | 11022022 | 10-Q 9/30/2022 |
| 6302022 | 7292022 | 10-Q 6/30/2022 |
| 3312022 | 4292022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | MCNAMARA KEVIN J | president and CEO | 11252025 | Sell | 437.55 | 2,000 | 875,100 | 41,215,897 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |